Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects
- PMID: 30593454
- DOI: 10.1136/gutjnl-2018-317839
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects
Keywords: infectious diarrhoea.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial.Gut. 2019 Jul;68(7):1224-1231. doi: 10.1136/gutjnl-2018-316794. Epub 2018 Sep 25. Gut. 2019. PMID: 30254135 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical